Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled? - SITC - SITC

Access Course

 

Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

 

This activity is intended for  oncologists, pulmonologists, and pathologists.

 

The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

 

 

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Nov. 9, 2018- Nov. 9, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers
  • Have greater competence related to how data may be integrated into the management of patients with advanced lung cancers
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s): 0.50